高层肿瘤学许可ADC技术公司针对HER3开发新的癌症治疗,可能支付多达368亿美元。 Elevation Oncology licenses ADC tech to develop new cancer therapy targeting HER3, with up to $368M in potential payments.

高层肿瘤学已经授权Synaffix的ADC技术 开发一个新的HER3癌症疗法 Elevation Oncology has licensed Synaffix's ADC technology to develop a new HER3-targeting cancer therapy. 根据该协定,提升使全球能够利用Synaffix公司先进的ADC平台,可能收到3.68亿美元里程碑付款。 Under the agreement, Elevation gains global access to Synaffix's advanced ADC platform, potentially receiving $368 million in milestone payments. 合作的目的是为显示HER3的固态肿瘤创造更安全、更有效的治疗方法,并预期在2025年提供临床前期数据。 The collaboration aims to create a safer and more effective treatment for solid tumors that express HER3, with preclinical data expected in 2025.